MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020
MannKind Corporation (NASDAQ:MNKD) will announce its 2020 third quarter financial results on November 4, 2020, at 5:00 PM ET. CEO Michael Castagna and CFO Steven Binder will discuss the results and corporate updates during a conference call. Interested parties can listen live via the company's website or join a telephone replay available for 14 days post-call. MannKind specializes in inhaled therapeutic products, notably the FDA-approved Afrezza® inhalation powder, the only inhaled ultra-rapid acting mealtime insulin available in the U.S. and Brazil.
- FDA-approved Afrezza® currently available by prescription in the U.S. and Brazil.
- Focused on developing inhaled therapeutic products for endocrine and orphan lung diseases.
- None.
WESTLAKE VILLAGE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, November 4, 2020.
Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven Binder.
Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com under News & Events.
A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (844) 512-2921 or (412) 317-6671 and use the participant passcode: 3965498#. A replay will also be available on MannKind's website for 14 days.
About MannKind Corporation
MannKind Corporation (NASDAQ: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil where it is commercialized by the Company’s partner Biomm SA. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Company Contact:
Phone: (818) 661-5000
Email: ir@mannkindcorp.com
FAQ
When will MannKind release its third quarter financial results?
Who will present the financial results during the conference call?
How can I listen to MannKind's conference call?
What is Afrezza and its significance for MannKind?
